Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $14.33 down -0.90% from its previous closing price of $14.46. In other words, the price has decreased by -$0.90 from its previous closing price. On the day, 0.94 million shares were traded. DAWN stock price reached its highest trading level at $14.9795 during the session, while it also had its lowest trading level at $14.01.
Ratios:
For a deeper understanding of Day One Biopharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.09 and its Current Ratio is at 4.09. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 10 ’24 when Blackman Samuel C. sold 30,000 shares for $14.22 per share. The transaction valued at 426,675 led to the insider holds 1,097,535 shares of the business.
Dubow Adam sold 3,202 shares of DAWN for $44,825 on Aug 16 ’24. The GENERAL COUNSEL now owns 26,928 shares after completing the transaction at $14.00 per share. On Aug 16 ’24, another insider, York Charles N II, who serves as the COO, CFO AND SECRETARY of the company, sold 2,633 shares for $14.00 each. As a result, the insider received 36,860 and left with 232,485 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1421593344 and an Enterprise Value of 895931328. For the stock, the TTM Price-to-Sale (P/S) ratio is 153.55 while its Price-to-Book (P/B) ratio in mrq is 4.10. Its current Enterprise Value per Revenue stands at 109.367 whereas that against EBITDA is -3.12.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $9.76. The 50-Day Moving Average of the stock is 1.54%, while the 200-Day Moving Average is calculated to be -1.77%.
Shares Statistics:
For the past three months, DAWN has traded an average of 1.00M shares per day and 961730 over the past ten days. A total of 87.23M shares are outstanding, with a floating share count of 59.32M. Insiders hold about 32.41% of the company’s shares, while institutions hold 73.68% stake in the company. Shares short for DAWN as of 1727654400 were 15667396 with a Short Ratio of 15.65, compared to 1724976000 on 14075501. Therefore, it implies a Short% of Shares Outstanding of 15667396 and a Short% of Float of 19.36.
